Development
Predictive Oncology Inc.
POAI
$0.9386
-$0.0114-1.20%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 715.10K | 490.10K | 239.90K | 363.50K | 455.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 715.10K | 490.10K | 239.90K | 363.50K | 455.80K |
| Cost of Revenue | 106.90K | 159.80K | 120.10K | 153.40K | 108.20K |
| Gross Profit | 608.10K | 330.30K | 119.80K | 210.00K | 347.70K |
| SG&A Expenses | 3.76M | 4.13M | 3.58M | 4.64M | 4.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.87M | 4.29M | 3.70M | 4.79M | 4.59M |
| Operating Income | -3.15M | -3.80M | -3.47M | -4.43M | -4.13M |
| Income Before Tax | -3.16M | -3.92M | -3.42M | -7.92M | -4.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.16M | -3.92M | -3.42M | -7.92M | -4.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.16M | -3.92M | -3.42M | -7.92M | -4.06M |
| EBIT | -3.15M | -3.80M | -3.47M | -4.43M | -4.13M |
| EBITDA | -2.99M | -3.62M | -3.23M | -4.10M | -3.80M |
| EPS Basic | -0.78 | -0.98 | -0.86 | -2.01 | -1.04 |
| Normalized Basic EPS | -0.49 | -0.59 | -0.54 | -0.70 | -0.65 |
| EPS Diluted | -0.78 | -0.98 | -0.86 | -2.01 | -1.04 |
| Normalized Diluted EPS | -0.49 | -0.59 | -0.54 | -0.70 | -0.65 |
| Average Basic Shares Outstanding | 4.03M | 4.00M | 3.97M | 3.94M | 3.92M |
| Average Diluted Shares Outstanding | 4.03M | 4.00M | 3.97M | 3.94M | 3.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |